Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis

Claudia Binda, Frantisek Hubálek, Min Li, Yaacov Herzig, Jeffrey Sterling, Dale E. Edmondson, Andrea Mattevi

Research output: Contribution to journalArticle

Abstract

Monoamine oxidases A and B (MAO A and B) catalyze the degradation of neurotransmitters and represent drug targets for the treatment of neurodegenerative disorders. Rasagiline is an irreversible, MAO B-selective inhibitor that has been approved as a novel anti-Parkinson's drug. In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues. Different substituents added onto the rasagiline scaffold alter the binding affinity depending on the position on the aminoindan ring and on the size of the substituent. Compounds with a hydroxyl group on either the C4 or the C6 atom inhibit both isozymes, whereas a bulkier substituent such as a carbamate is tolerated only at the C4 position. The 1.7 Å crystal structure of MAO B in complex with 4-(N-methyl-N-ethyl- carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan shows that the binding mode is similar to that of rasagiline with the carbamate moiety occupying the entrance cavity space. l(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B. The crystal structure of N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring adopts a different orientation compared to that of rasagiline.

Original languageEnglish (US)
Pages (from-to)8148-8154
Number of pages7
JournalJournal of Medicinal Chemistry
Volume48
Issue number26
DOIs
StatePublished - Dec 29 2005
Externally publishedYes

Fingerprint

Monoamine Oxidase
Kinetics
Carbamates
human monoamine oxidase A
rasagiline
Crystal structure
Scaffolds
Neurodegenerative Diseases
Pharmaceutical Preparations
Hydroxyl Radical
Isoenzymes
Neurotransmitter Agents
Degradation
Atoms

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Binda, C., Hubálek, F., Li, M., Herzig, Y., Sterling, J., Edmondson, D. E., & Mattevi, A. (2005). Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis. Journal of Medicinal Chemistry, 48(26), 8148-8154. https://doi.org/10.1021/jm0506266

Binding of rasagiline-related inhibitors to human monoamine oxidases : A kinetic and crystallographic analysis. / Binda, Claudia; Hubálek, Frantisek; Li, Min; Herzig, Yaacov; Sterling, Jeffrey; Edmondson, Dale E.; Mattevi, Andrea.

In: Journal of Medicinal Chemistry, Vol. 48, No. 26, 29.12.2005, p. 8148-8154.

Research output: Contribution to journalArticle

Binda, C, Hubálek, F, Li, M, Herzig, Y, Sterling, J, Edmondson, DE & Mattevi, A 2005, 'Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis', Journal of Medicinal Chemistry, vol. 48, no. 26, pp. 8148-8154. https://doi.org/10.1021/jm0506266
Binda, Claudia ; Hubálek, Frantisek ; Li, Min ; Herzig, Yaacov ; Sterling, Jeffrey ; Edmondson, Dale E. ; Mattevi, Andrea. / Binding of rasagiline-related inhibitors to human monoamine oxidases : A kinetic and crystallographic analysis. In: Journal of Medicinal Chemistry. 2005 ; Vol. 48, No. 26. pp. 8148-8154.
@article{ee8cf4a5ebda45209ad855d7ce7085ae,
title = "Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis",
abstract = "Monoamine oxidases A and B (MAO A and B) catalyze the degradation of neurotransmitters and represent drug targets for the treatment of neurodegenerative disorders. Rasagiline is an irreversible, MAO B-selective inhibitor that has been approved as a novel anti-Parkinson's drug. In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues. Different substituents added onto the rasagiline scaffold alter the binding affinity depending on the position on the aminoindan ring and on the size of the substituent. Compounds with a hydroxyl group on either the C4 or the C6 atom inhibit both isozymes, whereas a bulkier substituent such as a carbamate is tolerated only at the C4 position. The 1.7 {\AA} crystal structure of MAO B in complex with 4-(N-methyl-N-ethyl- carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan shows that the binding mode is similar to that of rasagiline with the carbamate moiety occupying the entrance cavity space. l(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B. The crystal structure of N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring adopts a different orientation compared to that of rasagiline.",
author = "Claudia Binda and Frantisek Hub{\'a}lek and Min Li and Yaacov Herzig and Jeffrey Sterling and Edmondson, {Dale E.} and Andrea Mattevi",
year = "2005",
month = "12",
day = "29",
doi = "10.1021/jm0506266",
language = "English (US)",
volume = "48",
pages = "8148--8154",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "26",

}

TY - JOUR

T1 - Binding of rasagiline-related inhibitors to human monoamine oxidases

T2 - A kinetic and crystallographic analysis

AU - Binda, Claudia

AU - Hubálek, Frantisek

AU - Li, Min

AU - Herzig, Yaacov

AU - Sterling, Jeffrey

AU - Edmondson, Dale E.

AU - Mattevi, Andrea

PY - 2005/12/29

Y1 - 2005/12/29

N2 - Monoamine oxidases A and B (MAO A and B) catalyze the degradation of neurotransmitters and represent drug targets for the treatment of neurodegenerative disorders. Rasagiline is an irreversible, MAO B-selective inhibitor that has been approved as a novel anti-Parkinson's drug. In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues. Different substituents added onto the rasagiline scaffold alter the binding affinity depending on the position on the aminoindan ring and on the size of the substituent. Compounds with a hydroxyl group on either the C4 or the C6 atom inhibit both isozymes, whereas a bulkier substituent such as a carbamate is tolerated only at the C4 position. The 1.7 Å crystal structure of MAO B in complex with 4-(N-methyl-N-ethyl- carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan shows that the binding mode is similar to that of rasagiline with the carbamate moiety occupying the entrance cavity space. l(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B. The crystal structure of N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring adopts a different orientation compared to that of rasagiline.

AB - Monoamine oxidases A and B (MAO A and B) catalyze the degradation of neurotransmitters and represent drug targets for the treatment of neurodegenerative disorders. Rasagiline is an irreversible, MAO B-selective inhibitor that has been approved as a novel anti-Parkinson's drug. In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues. Different substituents added onto the rasagiline scaffold alter the binding affinity depending on the position on the aminoindan ring and on the size of the substituent. Compounds with a hydroxyl group on either the C4 or the C6 atom inhibit both isozymes, whereas a bulkier substituent such as a carbamate is tolerated only at the C4 position. The 1.7 Å crystal structure of MAO B in complex with 4-(N-methyl-N-ethyl- carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan shows that the binding mode is similar to that of rasagiline with the carbamate moiety occupying the entrance cavity space. l(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B. The crystal structure of N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring adopts a different orientation compared to that of rasagiline.

UR - http://www.scopus.com/inward/record.url?scp=29744451969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29744451969&partnerID=8YFLogxK

U2 - 10.1021/jm0506266

DO - 10.1021/jm0506266

M3 - Article

C2 - 16366596

AN - SCOPUS:29744451969

VL - 48

SP - 8148

EP - 8154

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 26

ER -